UCB SA - Company Profile

Powered by

All the data and insights you need on UCB SA in one report.

  • Save hours of research time and resources with
    our up-to-date UCB SA Strategy Report

  • Understand UCB SA position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

UCB SA (UCB) is a biopharmaceutical company that is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company's marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson's disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, Germany, Italy, Spain, France, China, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Brussels-Capital Region, Belgium.

Gain a 360-degree view of UCB SA and make more informed decisions for your business Gain a 360-degree view of UCB SA and make more informed decisions for your business Find out more
Headquarters Belgium

Address Allee De La Recherche, 60, Anderlecht, 1070


Telephone 32 2 5599999

No of Employees 9,083

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange UCB (EBR)

Revenue (2022) $5.7B -4.8% (2022 vs 2021)

EPS XYZ

Net Income (2022) XYZ -17.9% (2022 vs 2021)

Market Cap* $24.2B

Net Profit Margin (2022) XYZ -13.9% (2022 vs 2021)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

UCB SA premium industry data and analytics

840+

Clinical Trials

Determine UCB SA go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

470+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for UCB SA’s relevant decision makers and contact details.

290+

Catalyst Calendar

Proactively evaluate UCB SA’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

160+

Marketed Drugs

Understand UCB SA’s commercialized product portfolio to stay one step ahead of the market.

90+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

90+

Pipeline Drugs

Identify which of UCB SA’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

30+

Sales & Consensus Forecasts

Understand the current and future drug revenue for UCB SA and assess market opportunity for new entrants with patient population 8-year forecasts.

20+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Investigators

Review investigator profiles and find information on trial contacts across UCB SA, including performance indicators like number of completed trials, and linked attributes such as rehiring statistics.

3

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for UCB SA (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

Products and Services

Products Brands
Product Indications: Cimzia
Neurology: Vimpat
Epilepsy Keppra
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand UCB SA portfolio and identify potential areas for collaboration Understand UCB SA portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Financing Agreements In January, the company invested in IMIDomics.
2023 New Products/Services In December, the company unveiled its extensive program of 29 studies.
2023 Regulatory Approval In December, the company's BIMZELX (bimekizumab) was approved by the Japanese Ministry of Health, Labour and Welfare to treat adults with psoriatic arthritis, non-radiographic axSpA and ankylosing spondylitis.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters UCB SA Johnson & Johnson Novartis AG AstraZeneca Plc GSK plc
Headquarters Belgium United States of America Switzerland United Kingdom United Kingdom
City Anderlecht New Brunswick Basel Cambridge Brentford
State/Province - New Jersey - England England
No. of Employees 9,083 131,900 76,057 89,900 70,212
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Jonathan Peacock Chairman Executive Board 2023 65
Fiona du Monceau Vice Chairwoman Executive Board 2022 45
Jean-Christophe Tellier Chief Executive Officer Senior Management 2014 64
Sandrine Dufour Chief Financial Officer; Executive Vice President Senior Management 2020 57
Iris Low-Friedrich, M.D. Executive Vice President - Global Projects and Development; Chief Medical Officer Senior Management 2008 62
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into UCB SA key executives to enhance your sales strategy Gain insight into UCB SA key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward